|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 114.18 USD | +1.43% |
|
+1.79% | +8.67% |
| 06:44pm | Can Nvidia Do It Again? |  |
| 06:21pm | Merck to Collaborate With Exelixis on Phase 3 Colorectal Cancer Trial | MT |
Business description: Merck & Co., Inc.
- sale of pharmaceutical products (73.9%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (15.5%);
- sale of animal health products (9.8%);
- other (0.8%).
Net sales are distributed geographically as follows: the United States (56.2%), Europe/Middle East/Africa (22.4%), Latin America (5.2%), Asia/Pacific (4.6%), Japan (4.2%), China (3%) and other (4.4%).
Number of employees: 74,000
Sales by Activity: Merck & Co., Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Pharmaceutical | 4.28TCr | 5.2TCr | 5.36TCr | 5.74TCr | 5.81TCr |
Animal Health | 556.8Cr | 555Cr | 562.5Cr | 587.7Cr | 635.4Cr |
Unallocated Other Revenues | 38Cr | 172.8Cr | 91Cr | 89Cr | 52Cr |
Geographical breakdown of sales: Merck & Co., Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 2.24TCr | 2.72TCr | 2.85TCr | 3.23TCr | 3.65TCr |
Europe, Middle East and Africa | 1.33TCr | 1.45TCr | 1.33TCr | 1.4TCr | 1.46TCr |
Latin America | 220.6Cr | 258.2Cr | 308.6Cr | 345.9Cr | 341Cr |
Asia Pacific (other than Japan and China) | 240.7Cr | 361.4Cr | 322.5Cr | 305.8Cr | 298.3Cr |
Other | 122.1Cr | 256.8Cr | 210.4Cr | 255.9Cr | 287.8Cr |
Japan | 272.6Cr | 362.9Cr | 316.4Cr | 328Cr | 271.1Cr |
China | 437.8Cr | 519.1Cr | 680.2Cr | 549.4Cr | 193.9Cr |
Executive Committee: Merck & Co., Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 59 | 01/07/2021 |
| Director of Finance/CFO | 57 | 01/04/2021 | |
Marjorie Green
CTO | Chief Tech/Sci/R&D Officer | - | - |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/08/2020 |
Joseph Romanelli
IRC | Investor Relations Contact | 52 | 01/01/1996 |
Composition of the Board of Directors: Merck & Co., Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 65 | 27/11/2007 |
Patricia Russo
BRD | Director/Board Member | 73 | 01/09/1995 |
Robert Davis
CHM | Chairman | 59 | 01/12/2022 |
Pamela Craig
BRD | Director/Board Member | 69 | 01/09/2015 |
Paul Rothman
BRD | Director/Board Member | 67 | 01/09/2015 |
Inge Thulin
BRD | Director/Board Member | 71 | 01/03/2018 |
Mary Coe
BRD | Director/Board Member | 58 | 18/03/2019 |
Kathy Warden
BRD | Director/Board Member | 53 | 16/03/2020 |
| Director/Board Member | 72 | 16/03/2020 | |
| Director/Board Member | 71 | 26/05/2020 |
Holdings: Merck & Co., Inc.
| Name | Equities | % | Valuation |
|---|---|---|---|
| 1,34,43,693 | 7.86% | 806 M $ | |
MODERNA, INC. 0.58% | 23,08,190 | 0.58% | 106 M $ |
PERSONALIS, INC. 15.84% | 1,40,44,943 | 15.84% | 78 M $ |
| 7,72,165 | 0.95% | 63 M $ | |
| 17,39,768 | 4.54% | 23 M $ | |
AKTIS ONCOLOGY, INC. 1.78% | 9,52,844 | 1.78% | 18 M $ |
EIKON THERAPEUTICS, INC. 3.08% | 16,66,666 | 3.08% | 16 M $ |
SUTRO BIOPHARMA, INC. 1.64% | 2,72,351 | 1.64% | 10 M $ |
ALECTOR, INC. 3.21% | 35,45,719 | 3.21% | 8 M $ |
EVAXION A/S 19.22% | 12,14,126 | 19.22% | 5 M $ |
Company details: Merck & Co., Inc.
Group companies: Merck & Co., Inc.
| Name | Category and Sector |
|---|---|
MSD Sharp & Dohme GmbH
 MSD Sharp & Dohme GmbH Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes pharmaceutical products & vaccines |
Pharmaceuticals: Major
|
Merck Sharp & Dohme LLC
 Merck Sharp & Dohme LLC Pharmaceuticals: MajorHealth Technology Operates as a research-intensive biopharmaceutical company that develops medicines and vaccines for cardiometabolic & respiratory diseases |
Pharmaceuticals: Major
|
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC Pharmaceuticals: MajorHealth Technology Operates as a research-intensive biopharmaceutical company that develops medicines and vaccines for cardiometabolic & respiratory diseases |
Pharmaceuticals: Major
|
MSD Finance BV
 MSD Finance BV MiscellaneousMiscellaneous Functions as an investment holding company |
Miscellaneous
|
Merck Sharp & Dohme Finance Europe Ltd.
 Merck Sharp & Dohme Finance Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Provides business support services |
Miscellaneous Commercial Services
|
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.43% | +1.79% | +48.11% | -0.96% | 28TCr | |
| +2.78% | +2.68% | +34.60% | +129.75% | 88TCr | |
| +0.02% | +2.22% | +50.32% | +44.25% | 55TCr | |
| +2.03% | +2.90% | +15.17% | +47.40% | 37TCr | |
| +2.15% | +1.06% | +24.30% | +13.90% | 33TCr | |
| +1.57% | +2.71% | +30.03% | +31.52% | 28TCr | |
| +1.24% | +0.96% | +33.82% | +15.57% | 28TCr | |
| +0.52% | -3.04% | -34.47% | -51.26% | 20TCr | |
| +2.02% | -1.47% | +20.12% | +48.31% | 18TCr | |
| +0.83% | -3.18% | +23.07% | +65.70% | 16TCr | |
| Average | +1.48% | +0.69% | +24.51% | +34.42% | 35.1TCr | |
| Weighted average by Cap. | +1.64% | +1.49% | +29.56% | +52.10% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRK Stock
- Company Merck & Co., Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition